BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 46.0
(-2.17%)
JPY 46.0
(-2.17%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.15 Billion | -1.2 Billion | -1.51 Billion | -1.76 Billion | -1.78 Billion | -1.45 Billion |
| Net Income | -1.16 Billion | -1.48 Billion | -1.48 Billion | -1.71 Billion | -1.85 Billion | -1.88 Billion |
| Depreciation & Amortization | 395 Thousand | 16.71 Million | 35.12 Million | 66.68 Million | 62.47 Million | 82.77 Million |
| Deferred income taxes | - | - | - | - | 46.07 Million | 241.12 Million |
| Stock-based compensation | - | - | - | - | 872 Thousand | 14.01 Million |
| Change in working capital | 3.51 Million | 16.87 Million | -15.26 Million | -12.18 Million | -17.19 Million | 117.99 Million |
| Other non-cash items | 8.05 Million | 245.73 Million | -50.1 Million | -107.13 Million | -16.82 Million | -32.93 Million |
| Investing Cash Flow | -7.64 Million | -1.76 Million | -17.56 Million | -36.21 Million | -106.87 Million | -185.11 Million |
| Investments in PPE | -7.64 Million | -1.76 Million | -17.64 Million | -35.27 Million | -110.13 Million | -175.25 Million |
| Acquisitions | - | - | 80 Thousand | - | 495 Thousand | -7.2 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -1.45 Million | - | - | -937 Thousand | 2.75 Million | -2.65 Million |
| Financing Cash Flow | 690.95 Million | 432.1 Million | 569.22 Million | 2.05 Billion | 8.52 Million | 15.81 Million |
| Debt repayment | -112.5 Million | -87.5 Million | -212.5 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -2.22 Million | - |
| Common Stock Issuance | 573.38 Million | 519.6 Million | 478.05 Million | 2.05 Billion | 10.75 Million | 15.81 Million |
| Other Financing Activities | 5.07 Million | - | 303.67 Million | 585 Thousand | -1000.00 | - |
| Accounts receivables | 49 Thousand | 16.53 Million | -16.3 Million | 376 Thousand | 181 Thousand | 76.17 Million |
| Accounts payables | -56 Thousand | -1.83 Million | 1.44 Million | -346 Thousand | -27.51 Million | 19.56 Million |
| Inventory | - | -238.33 Million | 47.61 Million | 82.98 Million | 4.32 Million | 27.56 Million |
| Other working capital | 3.51 Million | 240.51 Million | -48.02 Million | -95.19 Million | 5.81 Million | -5.31 Million |
| Cash at beginning of period | 1.53 Billion | 2.3 Billion | 3.26 Billion | 3.01 Billion | 4.9 Billion | 6.52 Billion |
| Cash at end of period | 1.05 Billion | 1.53 Billion | 2.3 Billion | 3.26 Billion | 3.01 Billion | 4.9 Billion |
| Capital Expenditure | -7.64 Million | -1.76 Million | -17.64 Million | -35.27 Million | -110.13 Million | -175.25 Million |
| Effect of forex changes on cash | - | - | - | 1000.00 | -2000.00 | - |
| Net cash flow / Change in cash | -473.6 Million | -774.05 Million | -960.36 Million | 247.03 Million | -1.88 Billion | -1.62 Billion |
| Free Cash Flow | -1.16 Billion | -1.2 Billion | -1.52 Billion | -1.8 Billion | -1.89 Billion | -1.63 Billion |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.16 Billion | -399.84 Million | -258.16 Million | -295.75 Million | -1.48 Billion | -260.25 Million |
| Depreciation & Amortization | 395 Thousand | 262 Thousand | - | 48 Thousand | 16.71 Million | 4.17 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 3.51 Million | - | - | - | 16.87 Million | - |
| Other non-cash items | 8.05 Million | 400.1 Million | 258.16 Million | 295.8 Million | 245.73 Million | 264.43 Million |
| Investing Cash Flow | -7.64 Million | - | - | - | -1.76 Million | - |
| Investments in PPE | -7.64 Million | - | - | - | -1.76 Million | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 690.95 Million | - | - | - | 432.1 Million | - |
| Debt repayment | -112.5 Million | - | - | - | -87.5 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 573.38 Million | - | - | - | 519.6 Million | - |
| Other Financing Activities | 5.07 Million | - | - | - | - | - |
| Accounts receivables | 49 Thousand | - | - | - | 16.53 Million | - |
| Accounts payables | -56 Thousand | - | - | - | -1.83 Million | - |
| Inventory | - | - | - | - | -238.33 Million | - |
| Other working capital | 3.51 Million | - | - | - | 240.51 Million | - |
| Cash at beginning of period | 1.53 Billion | 1.06 Billion | 1.26 Billion | 1.53 Billion | 2.3 Billion | 1.77 Billion |
| Cash at end of period | 1.05 Billion | 1.29 Billion | 1.06 Billion | 1.26 Billion | 1.53 Billion | 1.53 Billion |
| Capital Expenditure | -7.64 Million | - | - | - | -1.76 Million | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -473.6 Million | 233.75 Million | -200.8 Million | -266.97 Million | -774.05 Million | -246.1 Million |
| Free Cash Flow | -1.16 Billion | 524 Thousand | - | 96 Thousand | -1.2 Billion | 8.35 Million |
CLPBY
8129
6325
0H8I
BOKF
2324